Vascular Biogenics Ltd. (NASDAQ: VBLT) stock jumped 1.71% on Monday to $0.24 against a previous-day closing price of $0.23. With 0.24 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.05 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2400 whereas the lowest price it dropped to was $0.2300. The 52-week range on VBLT shows that it touched its highest point at $0.32 and its lowest point at $0.10 during that stretch. Beta for the stock currently stands at 0.81.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VBLT was up-trending over the past week, with a rise of 1.23%, but this was up by 7.40% over a month. Three-month performance dropped to -0.83% while six-month performance rose 69.88%. The stock gained 14.09% in the past year, while it has gained 98.33% so far this year.
Float and Shares Shorts:
At present, 78.39 million VBLT shares are outstanding with a float of 60.99 million shares on hand for trading. On Aug 30, 2023, short shares totaled 0.3 million, which was 0.38% higher than short shares on Jul 30, 2023. In addition to Prof. Dror Harats M.D. as the firm’s CEO & Director, Mr. Samuel Backenroth serves as its Chief Financial Officer.
Through their ownership of 14.05% of VBLT’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.53% of VBLT, in contrast to 1.42% held by mutual funds. Shares owned by individuals account for 0.05%. As the largest shareholder in VBLT with 0.52% of the stake, Telemetry Investments LLC holds 403,500 shares worth 403,500. A second-largest stockholder of VBLT, Morgan Stanley & Co. LLC, holds 321,220 shares, controlling over 0.41% of the firm’s shares. Group One Trading LP is the third largest shareholder in VBLT, holding 127,293 shares or 0.16% stake. With a 0.05% stake in VBLT, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 40,323 shares are owned by the mutual fund manager.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, VBLT reported revenue of $64.00k and operating income of -$9.61M. The EBITDA in the recently reported quarter was -$9.05M and diluted EPS was -$0.12.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VBLT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With VBLT analysts setting a high price target of $5.00 and a low target of $5.00, the average target price over the next 12 months is $5.00. Based on these targets, VBLT could surge 1983.33% to reach the target high and rise by 1983.33% to reach the target low. Reaching the average price target will result in a growth of 1983.33% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded VBLT stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 525,000 while 0 shares were sold.